Federal health officials are leaning toward lifting their recommended pause on the use of Johnson & Johnson’s coronavirus vaccine after finding only a limited number of additional cases of a rare blood clotting disorder among recipients. Instead, the Food and Drug Administration is considered likely to attach a warning to the vaccine’s label to inform health practitioners — and the public — about the exceedingly uncommon, but dangerous possible side effect... That fear has not materialized. Dr. Marks and Dr. Janet Woodcock, the F.D.A.’s acting commissioner, said the clotting disorder appeared to be nearly as rare as they had hoped it would be when they recommended the pause. “We’ve now received more cases, but it isn’t an avalanche,” Dr. Woodcock said. “We’re not seeing a big surge, which is a great relief.”